About Atheneos Ventures
Atheneos Ventures is a venture capital firm founded in 2009. It is primarily based out of Sunnyvale, United States. As of Aug 2014, Atheneos Ventures has invested in 7 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and HealthTech. Most recently it participated in the $***** Series A round of Armetheon A lot of funds co-invest with Atheneos Ventures, with names like AshHill sharing a substantial percentage of its portfolio. Atheneos Ventures has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A
Atheneos Ventures' List of Top Investments
Atheneos Ventures has a portfolio of 7 companies. Their most notable investments include Armetheon and CoMentis.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, HealthTech and 1 other sectors, across stages such as Series A stage. Here is the list of top investments by Atheneos Ventures:1. Armetheon
Armetheon is a clinical stage company focussed on developing small molecule therapies for cardiovascular disorders. Its lead candidate tecarfarin is a long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1) which is in late clinical stage development (phase 2/3) for treating patients with prosthetic heart valves and renal dysfunction. It is also developing budiodarone, an antiarrhythmic amiodarone analog which is being investigated for its potential to suppress ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs).
Key facts about Armetheon
- Founded Year: 2011
- Location: Santa Clara (United States)
- Stage: Series B
- Total Funding till date: $31.3M
- Employee Count: 1 as on May 31, 2026
- Investors: CDIB Capital Group, AshHill and 1 Other
- Latest Funding Round: Series B, Feb 05, 2015, $*****
2. CoMentis
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer’s disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Was re-named CoMentis following Athenagen's merger with Zapaq in 2006. Pipeline includes - BACE Inhibitor is in Discovery stage, Alpha-7 PAM is in Pre-clinical stage and APN1125 is in Phase-1 clinical trial stage.
Key facts about CoMentis
- Founded Year: 2004
- Location: San Francisco (United States)
- Stage: Deadpooled
- Total Funding till date: $92.2M
- Employee Count: 21 as on Apr 30, 2026
- Investors: Wellington Partners Venture Capital, Blackstone and 10 Others
- Latest Funding Round: Series D, Mar 16, 2016, $*****
Espero Biopharma, formed by the merger of Espero Pharmaceuticals and Armetheon (a speciality pharma company), is a clinical stage biopharmaceutical company engaged in the late-stage development and commercialization of novel drugs for cardiovascular diseases. The company's pipeline includes Tecarfarin for the treatment of thrombosis (Phase 3) and Budiodarone for the treatment of cardiac arrhythmias (Phase 2). Tecarfarin (Vitamin K epoxidase inhibitors) is currently positioned to be the oral anticoagulant (OAC) therapy of choice for patients who require anticoagulation with a Vitamin K antagonist (VKA)
Key facts about Espero Biopharma
- Founded Year: 2013
- Location: Jacksonville (United States)
- Stage: Deadpooled
- Total Funding till date: $33M
- Employee Count: 1 - 10 as on Jul 01, 2024
- Investors: CDIB Capital Group, Amkey Ventures and 4 Others
4. Altheos
Developer of next-generation eye drop for the treatment of glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company.
Key facts about Altheos
- Founded Year: 2010
- Location: San Francisco (United States)
- Stage: Deadpooled
- Total Funding till date: $32.5M
- Employee Count: 1 as on Mar 31, 2026
- Investors: Novo Holdings, Bay City Capital and 3 Others
- Latest Funding Round: Series A, Feb 09, 2012, $*****
5. Renexxion
Biotechnology firm innovating gastrointestinal disorder treatments with Naronapride. This US-based company, with an Irish subsidiary, focuses on developing and delivering innovative pharmaceutical drugs to address unmet needs in gastrointestinal health. Their pipeline centers around Naronapride, a novel therapeutic approach. The leadership team comprises seasoned biotech industry veterans with extensive experience in pharmaceutical drug development, management, and financing. They are dedicated to advancing gastrointestinal care through research, strategic partnerships, and a commitment to improving patient outcomes. The company operates in the biotechnology and pharmaceutical sectors, emphasizing innovation and patient-centric solutions for gastrointestinal disorders.
Key facts about Renexxion
- Founded Year: 2014
- Location: Menlo Park (United States)
- Stage: Funding Raised
- Employee Count: 12 as on Mar 31, 2026
- Investors: Atheneos Ventures
Atheneos Ventures' Investments by Stage
Atheneos Ventures has made 2 investments in Series A stage with an average round size of $13.5M.Atheneos Ventures' Investments by Sector
Atheneos Ventures has a portfolio focused on Life Sciences. Notably, it has invested in 6 Tech companies, 4 Enterprise (B2B) companies, 1 Consumer (B2C) company and 1 company focusing on Software.Atheneos Ventures' Investments by Geography
Atheneos Ventures has made most investments in United States (2).Atheneos Ventures' recent investments
Atheneos Ventures has not made any investment in 2026 so far.Here are the most recent investments by Atheneos Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 28, 2014 | United States | Series A | 3426 | ||
Apr 05, 2010 | United States | Series A | 2043 | [+3] |
Team profile of Atheneos Ventures
Atheneos Ventures has a team of 2 members including 1 Partner and 1 Venture Partner located in Spain and United States. Atheneos Ventures' team does not sit on the board of any company as of now.Co-investors of Atheneos Ventures
Over the past 16 years, 5 investors have co-invested in Atheneos Ventures's portfolio companies. This includes only funds.
- Top Co-investors of Atheneos Ventures: 5 investors entered a company along with Atheneos Ventures. These include investors like AshHill (1 company).
